首页|Beijing University of Chemical Technology Reports Findings in Nipah Virus [Immunoinformatics-driven In silico vaccine design for Nipah virus (NPV): Integrating machine learning and computational epitope prediction]
Beijing University of Chemical Technology Reports Findings in Nipah Virus [Immunoinformatics-driven In silico vaccine design for Nipah virus (NPV): Integrating machine learning and computational epitope prediction]
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NETL
NSTL
New research on RNA Viruses - Nipah Virus is the subject of a report. According to news reporting out of Beijing, People’s Republic of China, by NewsRx editors, research stated, “The Nipah virus (NPV) is a highly lethal virus, known for its significant fatality rate. The virus initially originated in Malaysia in 1998 and later led to outbreaks in nearby countries such as Bangladesh, Singapore, and India.” Our news journalists obtained a quote from the research from the Beijing University of Chemical Technology, “Currently, there are no specific vaccines available for this virus. The current work employed the reverse vaccinology method to conduct a comprehensive analysis of the entire proteome of the NPV virus. The aim was to identify and choose the most promising antigenic proteins that could serve as potential candidates for vaccine development. We have also designed B and T cell epitopes-based vaccine candidate using immunoinformatics approach. We have identified a total of 5 novel Cytotoxic T Lymphocytes (CTL), 5 Helper T Lymphocytes (HTL), and 6 linear B-cell potential antigenic epitopes which are novel and can be used for further vaccine development against Nipah virus. Then we performed the physicochemical properties, antigenic, immunogenic and allergenicity prediction of the designed vaccine candidate against NPV. Further, Computational analysis indicated that these epitopes possessed highly antigenic properties and were capable of interacting with immune receptors. The designed vaccine were then docked with the human immune receptors, namely TLR-2 and TLR-4 showed robust interaction with the immune receptor. Molecular dynamics simulations demonstrated robust binding and good dynamics. After numerous dosages at varied intervals, computational immune response modeling showed that the immunogenic construct might elicit a significant immune response.”
BeijingPeople’s Republic of ChinaAsiaBiological ProductsCyborgsEmerging TechnologiesHealth and MedicineHendra VirusImmunizationMachine LearningMedical DevicesMononegaviralesNipah VirusParamyxoviridaeParamyxovirinaeRNA VirusesVaccinationVaccine DevelopmentVaccinesVirologyViruses
NETL
NSTL
